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ABSTRACT 
Objective: We aimed to test whether a national Enhanced Recovery After Surgery (ERAS) 
Programme in total knee replacement (TKR) had an impact on patient outcomes. 
Design: Natural-experiment (April 2008-December 2016). Interrupted time-series regression 
assessed impact on trends before-during-after ERAS implementation.  
Setting: Primary operations from the UK National Joint Registry were linked with Hospital 
Episode Statistics data which contains inpatient episodes undertaken in NHS trusts in 
England, and PROMs. 
Participants: Patients undergoing primary planned TKR aged ≥18 years. 
Intervention: ERAS implementation (April 2009-March 2011). 
Outcomes: Regression coefficients of monthly means of LOS, bed day costs, change in 
Oxford knee scores (OKS) 6-months after surgery, complications (at 6 months), and rates of 
revision surgeries (at 5 years). 
Results: 486,579 primary TKRs were identified. Overall LOS and bed-day costs decreased 
from 5.8 days to 3.7 and from £7607 to £5276, from April 2008 to December 2016. OKS 
change improved from 15.1 points in April 2008 to 17.1 points in December 2016. 
Complications decreased from 4.1 % in April 2008 to 1.7 % March 2016. 5-year revision 
rates remained stable at 4.8 per 1000 implants years in April 2008 and December 2011. After 
ERAS, declining trends in LOS and bed costs slowed down; OKS improved, complications 
remained stable, and revisions slightly increased. 
Conclusions: Different secular trends in outcomes for patients having TKR have been 
observed over the last decade. Although patient outcomes are better than a decade ago ERAS 
did not improve them at national level. 
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INTRODUCTION 1 
Between April 2009 and March 2011 the UK Department of Health implemented an 2 
Enhanced Recovery After Surgery (ERAS) Partnership Programme[1] to improve recovery in 3 
colorectal, musculoskeletal, gynaecology and urology surgical pathways. The first year of the 4 
programme focussed on learning best practice from pioneer units of ERAS practice in the 5 
NHS. It collected information about principles of enhanced recovery, clinical elements of the 6 
patient pathway, metrics and success factors. It established a website to share information and 7 
resources, generated a financial and equality impact evaluation, published an implementation 8 
guide, and developed an online reporting tool to support implementation. A lead for enhanced 9 
recovery was named in each local health authority to prepare for a programme of spread and 10 
adoption across the NHS during the ERAS implementation in the second year of the 11 
programme. 12 
 13 
Hip and knee replacement were the focus of ERAS in musculoskeletal care. ERAS is a 14 
complex intervention[2, 3] that focuses on several areas of care across patients’ pathways 15 
through surgery: pre-operatively (for the patient to be in the best possible condition for 16 
surgery); peri-operatively[4] (the patient has the best possible management during and after 17 
their operation); post-operatively (the patient experiences the best rehabilitation). The 18 
intervention includes provision of information before and after surgery, comprising elements 19 
such as making changes around the home, strengthening exercises, and changes to nutrition. 20 
For patients in whom it is suitable, ERAS aims to enable earlier return home from hospital 21 
with tailored discharge. A greater number of frail older people with complex co-morbid 22 
conditions now receive hip/knee replacement surgery. The new ERAS pathways’ could 23 
specifically benefit these patient groups[5]. 24 
  25 
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There is limited evidence concerning the effectiveness of ERAS programmes[6], particularly 26 
when applied nationwide across a healthcare system with variation in the way hospitals 27 
organise enhanced recovery services and it is unclear which way is best. Length of stay 28 
(LOS) has been declining prior to the intervention, and we hypothesised that after the 29 
implementation of ERAS, this downward secular trend would decline faster. For the 30 
outcomes of complications, revision, pain and function, we did not have a specific a-prior 31 
hypothesis as it is unclear what impact ERAS would have on these outcomes. Our aim is to 32 
see if introduction of the ERAS programme for knee replacement has led to improved patient 33 
outcomes: less knee pain and better knee function, fewer surgical complications, fewer 34 
revision operations and reduced LOS.   35 
 36 
METHODS 37 
Study design 38 
We used a natural experimental study design[19]. We evaluated the impact of ERAS on 39 
trends before (April 2008 to March 2009), during (April 2009 to March 2011) and after the 40 
intervention (April 2011 to December 2016) [20, 21] (Supplementary Figure S1). The timing 41 
of implementation of ERAS varied by trust and was assumed to span the 2 years of the 42 
implementation period (April 2009 to March 2011).  43 
 44 
Participants and inclusion criteria 45 
We included only patients receiving elective surgery (Fig. 1) between 1 April 2008, and 31 46 
December 2016. We excluded patients without a concordant date of surgery between the UK 47 
National Joint Registry (NJR) and Hospital Episode Statistics (HES) databases. 48 
 49 
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Further exclusions were made specific to the outcome being analysed. For LOS we excluded 50 
patients staying more than 15 days at hospital. Patients with missing data for LOS were 51 
excluded. We excluded patients without information on baseline and/or 6-months follow-up 52 
for the analysis of change in OKS. However, we used all patients in a sensitivity analysis 53 
after imputing missing values. For complications we excluded patients with surgery after 54 
June 2016 to guarantee all patients had at least 6-months of follow up. For revision at 5 years 55 
we excluded patients receiving surgery after 2011 to ensure all patients had at least 5-years 56 
follow up.  57 
 58 
[Fig. 1. near here]  59 
 60 
Data source 61 
We used the NJR to obtain data on primary knee replacements. NJR contains data on knee 62 
replacement surgeries from 149 UK National Health Service (NHS) trusts. NJR includes 2 63 
million patients since 2003, covering 96% and 90% of primary knee replacements and knee 64 
revisions, respectively[7].   65 
 66 
Data linkages 67 
Primary operations were linked with HES data which contains records of all inpatient 68 
episodes undertaken in NHS trusts in England (125 million each year). Knee replacements 69 
were linked to Patient Reported Outcome Measures (PROMs). A cohort of patients 70 
undergoing primary total knee replacement (TKR) in England, UK, was retrieved for the 71 
period April 2008 to December 2016.  72 
 73 
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Outcome measures 74 
We evaluated trends for LOS at hospital for patients undergoing primary TKR. LOS was 75 
calculated as the number of days between hospital admission and discharge date. Time points 76 
for the trends were monthly mean LOS. We estimated the inpatient cost relating to the index 77 
episode using NHS reference costs from 2015/16[8]. We estimated the mean cost per bed day 78 
based on the healthcare resource use (HRG) for each patient and their LOS (Appendix 1). 79 
Monthly mean bed-day costs were the unit of analysis for costs trends. 80 
 81 
We assessed absolute change in OKS. Patients complete the same questionnaire about their 82 
knee pain and function before and 6 months after surgery[9]. Each question is scored between 83 
0 (worse symptoms) and 4 (least symptoms). Scores from these 12 questions are added 84 
getting a total score spanning from 0 (worst possible) and 48 (best possible score). We 85 
calculated the absolute difference (change) between baseline and 6-month follow-up scores. 86 
Higher positive values for OKS change measure represented greater improvement. OKS 87 
trends were obtained by calculating the monthly mean OKS change scores.  88 
 89 
We estimated mean 6-month complication proportions aggregated by month. We defined 90 
post-operative complications as one or more events from the following list: stroke (excluding 91 
transient ischaemic attack), respiratory infection, acute myocardial infarction, pulmonary 92 
embolism/deep vein thrombosis, urinary tract infection, wound disruption, surgical site 93 
infection, fracture after implant, complication of prosthesis, neurovascular injury, acute renal 94 
failure and blood transfusion (Appendixes 2 and 3).  95 
 96 
We evaluated the rate of revision at 5 years by month of primary TKR. We included revisions 97 
declared to the NJR registry by the surgeons[10] and revisions reported to HES using codes 98 
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from Appendix 4. We specified our analysis time in years reporting the rate as number of 99 
revisions per 1000 implant-years. 100 
 101 
Intervention  102 
The period of the national ERAS implementation (April 2009 to March 2011). During the 103 
first year the programme focused on identifying best practice, determining clinical elements 104 
of the patient pathway, publishing an implementation guide, supporting early adopters of the 105 
programme to better understand key factors for implementation and sustainability[11].  106 
During the second year ERAS supported local health areas for delivering and commissioning 107 
implementation of ERAS. 108 
 109 
Potential modifiers 110 
Whether trends in LOS and OKS differed by age (18-59, 60-69, 70-79, 80-84, ≥85 years) and 111 
presence of co-morbidities according to the Charlson classification[12] (none versus one or 112 
more comorbidities) (Appendix 5). 113 
 114 
Missing data  115 
We used Pearson's χ2 statistic to evaluate missingness for OKS across categories of study 116 
period (before, during, and after ERAS), age and presence of co-morbidities. OKS at baseline 117 
and 6 months was imputed as a sensitivity analysis. We generated a single imputed dataset 118 
using a chained equation across 50 iterations to reach a stationary distribution. 119 
 120 
Statistical analysis 121 
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We described the trends by calculating monthly outcomes, being means (LOS, bed costs, 122 
OKS), proportions (complications), rates (revision), together with their 95% confidence 123 
intervals (CI). We estimated a fractional polynomial over the study period and plotted the 124 
resulting curve along with the confidence interval of the mean. 125 
 126 
We used an interrupted time series approach to estimate changes in outcomes during and 127 
immediately following the intervention period while controlling for baseline levels and 128 
trends. We modelled aggregated data points of each outcome of interest by month using 129 
segmented linear regression[13]. 130 
 131 
Yt = β0 + (β1 * time t) + (β2 * ERAS0) + (β3 * time after ERAS0) + (β4 * ERAS end) + (β5 * time 132 
after ERAS end) + et. 133 
 134 
Yt is the mean number of days at hospital in month t for LOS outcome; mean OKS change in 135 
month t for the PROMs outcome; mean proportion of complications in month t for the 6-136 
month complications outcome; and mean rate of revisions in month t for the 5-year revision 137 
outcome. “time” is a continuous variable representing number of months from the start of 138 
observation period at time t. Each phase of the study has two parameters: baseline level and 139 
trend:  140 
• Pre-intervention period. β0 estimates the baseline level of the outcome at the 141 
beginning of the time series (i.e., April 2008). β1 estimates the trend before ERAS 142 
implementation (i.e., before April 2009).  143 
• Intervention period. β2 is the change in level immediately following the intervention 144 
(ERAS0 = April 2009). β3 estimates the change in the trend in the monthly mean 145 
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(number or rate depending of outcome) after ERAS started (i.e., ERAS 146 
implementation trend).  147 
• Post-intervention period. β4 is the change in level immediately following the end of 148 
the intervention (ERAS end = March 2011). β5 estimates the change in the trend in the 149 
mean monthly number or rate (depending of outcome) after ERAS ended (i.e., ERAS 150 
post-implementation trend).  151 
In preliminary analysis we checked the autocorrelation with the previous month, two 152 
months… until the previous 12 months using Durbin's alternative test[14]. We estimated 153 
linear regression models with Newey-West standard errors[15].  154 
 155 
All analyses were conducted using Stata version 13.1 (StataCorp, College Station, Texas). 156 
We followed the STROBE (Strengthening the Reporting of Observational Studies in 157 
Epidemiology) guideline[16]. 158 
 159 
RESULTS 160 
Between April 2008 and December 2016 there were 486,579 planned primary TKR (Fig. 1). 161 
57% of patients were women, the average age was 70 years (SD ±9 years). Mean body mass 162 
index (BMI) pointed to a nutritional status of obesity class I 31.0 kg/m2 (SD ±5.5 kg/m2)[17]. 163 
The physical status[18] of patients was mild or fit for 83% according to the American Society 164 
of Anesthesiologists (ASA grade). 165 
 166 
LOS 167 
479,353 patients were used for the analysis of LOS (Fig. 1). LOS decreased from 5.8 days 168 
(95% CI: 5.7 to 5.9) in April 2008 to 3.7 (95% CI: 3.7 to 3.8) in December 2016 (Fig. 2A). 169 
Prior to ERAS LOS was already decreasing significantly by -0.032% every month (95% CI: -170 
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0.035% to -0.028%) (Table 1). The rate of reduction in mean LOS declined at a slower rate (-171 
0.016%, i.e. baseline trend - trend change after ERAS) after the intervention period (April 172 
2011 to December 2016). 173 
 174 
[Fig. 2 and Table 1 near here] 175 
 176 
Although older patients had a longer LOS, the secular trends in decreasing LOS were seen 177 
across all age groups (e.g. 5.1 days (95% CI: 4.9 to 5.4) to 3.3 days (95% CI: 3.1 to 3.4) in 178 
those age 18-59 and 7.7 days (95% CI: 7.2 to 8.2) to 5.4 days (95% CI: 5.1 to 5.8) in age 179 
≥85) (Fig. 3, Supplementary Table S1). Secular trends also decreased in patients with and 180 
without pre-existing co-morbidity (Fig. 4). Cost data were estimated for a total of 479,353 181 
patients. The results for mean inpatient bed day cost over time shows a similar trend to that 182 
observed for LOS. Overall mean cost of the index hospital episode decreased from £7607 183 
(95% CI: £7511 to £7704) in April 2008 to £5276 (95% CI: £5213 to £5339) in December 184 
2016 (Fig 5). 185 
 186 
[Figs 3-5 near here] 187 
 188 
OKS change 189 
We excluded 48% of patients with missing information for OKS in the analysis of change in 190 
PROMs (Figure 1). We found more missing data for OKS change prior to ERAS (88.6%) 191 
than in the implementation period or after ERAS (43.0% and 45.0%, respectively) 192 
(Supplementary Table S2).  Supplementary Table S3 shows more patients without data for 193 
OKS change than with data in the period prior to ERAS (15.7% and 1.9%, respectively).  194 
 195 
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Over the study period there was an improvement in OKS change 6 months after surgery of 196 
15.1 points (95% CI: 14.1 to 16.2) in April 2008, to 17.1 points (95% CI: 16.2 to 18.1) in 197 
December 2016 (Fig. 2B). The improvement in the secular trends was observed across all age 198 
categories and patients with and without co-morbidity (Figs. 6 and 7, Supplementary Table 199 
S4). For the sensitivity analysis imputing OKS change we observed similar results 200 
(Supplementary Figs. S2 and S3, Supplementary Tables S5 and S6) 201 
 202 
[Fig. 6 and Fig. 7 near here] 203 
 204 
The interrupted time-series model for OKS change shows that prior to ERAS OKS change 205 
increased by 0.052% (95% CI: -0.044% to 0.148%) every month (Table 1) and in the imputed 206 
dataset by 0.053% (95% CI: 0.042% to 0.064%) (Supplementary Table S5). During ERAS 207 
implementation (April 2009 to March 2011) the secular trend slowed down by 0.009 and 208 
increased significantly again after ERAS by 0.071. 209 
 210 
Complication at 6-months 211 
6,884 (1.6%) patients had one or more complications 6 months after TKR. The proportion of 212 
complications decreased from 4.1% (95% CI: 3.5 to 4.8) to 1.7% (95% CI: 1.3 to 2.0) (Fig. 213 
2C). The interrupted time-series model for complications at 6 months shows that prior to 214 
ERAS complication proportion decreased by -0.058% every month (95% CI: -0.071% to -215 
0.045%) (Table 1). The period after the ERAS intervention remained stable. 216 
 217 
5-year revision rates 218 
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3,917 (2.2%) patients had a knee revision in the following 5 years according to the NJR 219 
registry. We found 30 more 5-year revisions using HES giving a total of 3,947 (2.2%). Rates 220 
of 5-year knee revision per 1000 implant year remained unchanged with a rate of 4.8 per 221 
1000 implants years (95% CI: 3.9 to 6.0) at risk in April 2008 and 4.8 (95% CI: 3.9 to 5.9) in 222 
December 2011 (Fig. 2D). 223 
  224 
The model for 5-year knee-revision rates shows a significant downward trend of -0.031 per 225 
1000 implants years (95% CI: -0.058 to -0.003) during ERAS implementation (April 2009 to 226 
March 2011) (Table 1). The trend changed direction by increasing during the post-227 
intervention period (April 2011 to December 2016) in 0.040 per 1000 implants years (95% 228 
CI: 0.021 to 0.060).  229 
 230 
DISCUSSION 231 
Prior to the introduction of ERAS LOS and inpatient bed-day cost was declining. Although 232 
LOS and inpatient bed-day cost continued to decrease after ERAS implementation, this was 233 
at half the rate of decline. The absolute change in OKS was higher following ERAS 234 
implementation, but although significant, it did not reach clinical significance. There was no 235 
change in complications, while the 5-year revision trend slightly increases after ERAS. LOS 236 
and OKS trends were seen across all age groups, and in those with and without co-morbidity. 237 
Reductions in LOS have been achieved without adversely impacting on patient outcomes. 238 
However, implementation of ERAS either slowed down or maintained pre-existing secular 239 
trends.  240 
 241 
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We know from other UK studies that length of stay has been in gradual decline in the years 242 
prior to 2008, where Burn et al found that in 1997 mean LOS for TKR was 18.89 days, and in 243 
2008, before the ERAS intervention, 7.49 days [19]. We expected to observe a steeper trend 244 
in the decrease in length of stay after the intervention period (2009-2011). Although we did 245 
not a-priori know what pattern would be expected prior to ERAS for the other outcomes, we 246 
hypothesized that following the intervention, outcomes of patient reported pain and function, 247 
complications, and revision surgery should improve. 248 
 249 
Our assumptions, for this “natural experiment” of the implementation of ERAS, were that 250 
this large scale intervention was implemented homogenously across all England NHS trusts 251 
spanning this 2-year period. There was already an encouraging trend towards reduction in 252 
LOS and improved outcomes that had begun prior to the official EPR programme. This is 253 
likely to reflect early adoption of elements of ERAS methods in some Trusts, prior to the start 254 
of the Department of Health led programme in 2009. Not all hospitals had implemented 255 
ERAS at the end of the implementation period (March 2011)[11]. The survey on the spread 256 
and adoption of ERAS carried out close to the end of the implementation (February 2011) by 257 
the Department of Health reported full implementation in 81 consultant teams, while about 20 258 
had partially implemented ERAS, and about 30 still planned to implement ERAS. A 259 
limitation is the variation in interpretation and adoption across centres because what 260 
constitutes ERAS was not clearly established after the expected identification of best 261 
practices in the first year of the ERAS programme[20]. 262 
 263 
Dates of implementation of ERAS were different among hospitals. How long that 264 
implementation could span or actually spanned are not provided in the Department of Health 265 
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guideline or in the subsequent report[11, 20]. Because of the complexity of the intervention 266 
and stakeholders involved this could vary between hospitals. Therefore, our quasi-267 
experimental approach smoothed dissimilarities in times used to adopt the ERAS 268 
intervention.  269 
 270 
External influencing factors 271 
Our results show trends in outcomes that has been achieved in the context of an increasing 272 
strain on NHS funding and hospital budgets. NHS funding growth is much slower than the 273 
historical long term trend[21]. There are fewer hospital beds and wards have been closed. For 274 
example, the average daily number of occupied beds open overnight for trauma and 275 
orthopaedics for England between April and June 2010 was 10,015 while in October to 276 
December 2016 was 8,770[22]. Conversely, the number of primary knee replacements 277 
increased from 74,277 in 2008 to 98,147 in 2016[23] in England. It has been estimated that 278 
118,666 TKRs will take place by the year 2035[24]. Further to this, the complexity of 279 
patients has changed over time, with more patients with co-morbidities now receiving 280 
surgery. Efficiencies need to be made to meet this demand within existing or lower capacity. 281 
An important issue is the high variation in services and practices across hospitals in England. 282 
The Getting It Right First Time (GIRFT) programme aims to reduce discrepancies between 283 
hospitals showing diversity in activity volumes, implant choice, and guidelines follow-284 
up[25]. The first GIRFT report was published in 2012, while the improving trends in 285 
outcomes in our study are detected since 2008. Although our results of a positive national 286 
trend are encouraging, there still remains substantial variation in outcomes between hospital 287 
trusts. In 2016, mean LOS varied between a low of 2.2 days to a high of 5.6, and OKS 288 
between 12.8 and 22.3 points. Hence although the national picture has improved for patients 289 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Assessment of National Enhanced Recovery Programme 
13 
 
as a whole, there is still work to be done to reduce and understand unwarranted variations in 290 
outcome between individual hospitals. 291 
 292 
Many studies supporting the implementation of ERAS pathways have been placed in single 293 
institutions or rather small trials[26]. Thus, they may not be generalizable to the wider 294 
population. Reductions in LOS prior to the official implementation of ERAS may reflect a 295 
commitment to improving the cost-effectiveness of this surgery which represents an 296 
important expenditure for the NHS [19, 27, 28]. Reduction in LOS has been reported in 297 
systematic reviews and randomised clinical trials comparing patients following an ERAS 298 
programme for colorectal and other planned surgeries against those under conventional 299 
care[6]. There is variation in the type of ERAS intervention for knee replacement that has 300 
been evaluated among previous studies[29][30, 31][32][33][34][29-35] that preclude us to 301 
make generalizations at a nationwide level. Additionally, these studies were limited to only 302 
one hospital or trust. Moreover, they were focused on the comparison of the intervention with 303 
traditional management. Our study investigates whether the ERAS pathway has been 304 
successfully implemented comparing with a previous period without ERAS, as has been done 305 
in other studies[30-32], but also, and for first time, comparing with the post-intervention 306 
period. 307 
 308 
The decreasing trend in LOS over time was also reflected in the change in estimated average 309 
inpatient bed day cost. We found that the majority of episodes in the data had a LOS less than 310 
the trim point for the relevant cost HRG. This meant that (assigning the same unit cost to all 311 
patients with the same HRG who had a LOS below the trim point) the reduction in LOS 312 
within the trim point would not be reflected by a change in the estimated average episode 313 
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costs. We therefore estimated the true reduction in NHS expenditure by estimating a cost per 314 
bed day reflecting the LOS for each patient. 315 
 316 
OKS change scores increased across the study period. However, the change of ~2-3 points 317 
using complete and imputed cases does not reaching the clinically meaningful difference of 5 318 
points suggested within the literature[36]. A review on ERAS in total hip replacement shows 319 
that better improvement in pain and function scores could be related to making patients active 320 
participants in their recovery and to help them to manage their expectations[28]. A Cochrane 321 
review on preoperative education for hip or knee replacement did not find additional benefits 322 
over usual care[37]. However, non-significant reduction of pain and better function were 323 
reported to be associated with preoperative education. 324 
 325 
The 6-month complications were decreasing until the implementation took place. 326 
Subsequently, the trend remained steady during the ERAS period and slightly increased 327 
following the intervention. Potentially, discharging patients too soon after surgery could 328 
increase complications. However, a meta-analysis in colorectal surgery on several ERAS 329 
programmes did not find evidence of an increased risk of surgical complications[38], and 330 
found that cardiovascular, pulmonary, and infectious medical complications decreased.  331 
Patients with diabetes undergoing hip and knee replacement under ERAS protocols reduce 332 
the additional risk for complications otherwise associated with operating patients with 333 
diabetes[39]. A limitation is that manipulation under anaesthesia was not considered among 334 
the list of 6-month complications. Werner et al. found 4.24% requiring manipulation under 335 
anaesthesia by 6 months in a large cohort of patients undergoing TKR (n=141,016). 4.8% of 336 
them had a revision within the following 7 years[40].  337 
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 338 
5-year revision rates diminished across the study. It has been an important effort to reduce 339 
revision rates because the procedure is more complicated to perform[41]. Surveillance of 340 
knee replacement revisions, using joint registries, have long been the main measure of 341 
primary surgical success/failure until PROMs were also used to assess outcomes[42]. 342 
Revision rates could have declined as a consequence of patient selection for primary 343 
surgery[43].  344 
  345 
To inform the list of important outcomes for this study, we conducted a forum with the 346 
University of Bristol’s Musculoskeletal Research Unit’s patient involvement group. Mortality 347 
was ranked low by the group in respect of its importance to them, and hence has not been 348 
included and remains a limitation of the analysis. We did not included BMI as a potential 349 
modifier for trends in LOS and OKS. A slightly higher proportion of obese patients (≥35 350 
Kg/m2) between 2008 and 2016 (21.4% and 25.3%, respectively) might influence trends for 351 
LOS and OKS, respectively. 352 
 353 
Conclusion 354 
Our study shows that trends of improved outcomes of planned TKR slowed down after 355 
ERAS. LOS, OKS, complications and revisions are currently better than 10 years ago. LOS 356 
has declined substantially over the study period, consistent across all age groups and in 357 
people with and without co-morbidity. Nevertheless, declines in LOS were half the initial 358 
decline following ERAS implementation. Reductions in LOS have been achieved without 359 
adversely impacting on patient outcomes. Patient reported outcomes in respect of pain and 360 
function have improved, but did not reach clinical significance. Complication rates remain 361 
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stable and revision rates decline less than before ERAS implementation.  These trends in 362 
outcomes have been achieved in the context of reductions in the numbers of available 363 
beds/wards/operating theatres, with increasing absolute numbers of patients undergoing TKR 364 
year on year and sicker patients over the study time. 365 
 366 
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FIGURE LEGENDS 521 
Fig. 1. Flow diagram on selection of patients. 522 
 523 
Fig. 2. Trends in outcomes following primary TKR in England, UK, 2008- 2016, by 524 
month.   525 
2A, length of stay at hospital; 2B, change in self-reported pain and function, measured using 526 
Oxford knee score (OKS) at baseline and 6 months after the surgery; 2C, any complication in 527 
the following 6 months after primary TKR; 2D, knee revision in the following 5 years; 528 
enhanced recovery after surgery programme implemented in England from April 2009 to 529 
March 2011, ERAS. 530 
 531 
Fig. 3. Trends of length of stay at hospital following primary TKR according to age 532 
categories in England, UK, 2008 –2016, by month.  533 
Total knee replacement, TKR; enhanced recovery after surgery programme implemented in 534 
England from April 2009 to March 2011, ERAS. 535 
 536 
Fig. 4. Trends of length of stay at hospital following primary TKR by patients 537 
with/without comorbidities in England, UK, 2008 –2016, by month. 538 
Total knee replacement, TKR; enhanced recovery after surgery programme implemented in 539 
England from April 2009 to March 2011, ERAS. 540 
 541 
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Fig. 5. Trends of cost per bed day following primary TKR in England, UK, 2008 – 2016, 542 
by month. 543 
Total knee replacement, TKR; enhanced recovery after surgery programme implemented in 544 
England from April 2009 to March 2011, ERAS. 545 
 546 
Fig. 6. Trends of OKS change following primary TKR according to age categories in 547 
England, UK, 2008 – 2016, by month. 548 
Oxford knee score, OKS; total knee replacement, TKR; enhanced recovery after surgery 549 
programme implemented in England from April 2009 to March 2011, ERAS. 550 
 551 
Fig. 7. Trends of OKS change following primary TKR by patients with/without 552 
comorbidities in England, UK, 2008 –2016, by month. 553 
Oxford knee score, OKS; total knee replacement, TKR; enhanced recovery after surgery 554 
programme implemented in England from April 2009 to March 2011, ERAS. 555 
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APPENDIXES 
Appendix 1. Cost methods. 
Objective 
We aimed to estimate the trend in National Health Service (NHS) expenditure over time, 
reflecting the change in length of stay (LOS) observed.   
Grouper and reference cost methods 
Using Hospital Episode Statistics (HES) data for the same group of patients as for LOS (i.e. 
excluding those with length of stay above 15 days), we generated healthcare resource use 
group (HRG) classifications for the index episode for each patient using the 2015/16 NHS 
reference costs grouper [1], which were subsequently used to estimate inpatient costs per 
patient using NHS reference costs from 2015/16 [2]. 
A reduction in LOS within the trim point is therefore not reflected in the cost of the episode, 
despite there being a true reduction in NHS costs.  In order to estimate the mean change in 
NHS expenditure we therefore estimated an adjusted average bed day cost. 
Estimating the adjusted average bed day cost 
For each HRG we estimated the average cost per bed day (defined as any part of a day spent 
in hospital) by dividing the total cost of the index episodes for that HRG by the total number 
of bed days for that HRG. This generated a single average bed day cost per HRG.  
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For each patient we estimated the adjusted episode cost by multiplying their length of stay 
(bed days) by the average bed day cost for the HRG that they had been assigned by the NHS 
reference costs grouper [1]. Therefore, instead of assigning the same unit cost to all patients 
with the same HRG who had a LOS below the trim point, the adjusted cost differed according 
to a patient’s LOS, even if that LOS was below the trim point for the HRG. Using this 
method we were able to estimate the average difference in true NHS expenditure as a result 
of the reduction in length of stay over time even when the LOS was below the trim point. 
The 2015/16 grouper and reference costs [1,2] were used to estimate costs for all patients in 
all years, as there are differences in the methodologies used for HRG classification in 
different cost years [3]. This prevents a like-for-like comparison between years if different 
groupers and/or costs are used. 
Costs were estimated for a total of 517,798 patients.  
References for Appendix 1 
1. HRG4+ 2015/16 Reference Costs Grouper. Copyright © 2015 Health and Social Care 
Information Centre. Grouper version: RC 15/16. Implementation version: 1516.RC.8 
2. Department of Health. NHS reference costs 2015 to 2016. 
https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 
3. Reference Costs 2015-16. Department of Health. 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme
nt_data/file/577083/Reference_Costs_2015-16.pdf. 
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Appendix 2. Codes defined in the International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10) that we used to identify complications in 
the Hospital Episode Statistics (HES) registry. 
Stroke: I60.X, “Subarachnoid haemorrhage”; I61.0, “Intracerebral haemorrhage in 
hemisphere, subcortical”; I61.1, “Intracerebral haemorrhage in hemisphere, cortical”; I61.2, 
“Intracerebral haemorrhage in hemisphere, unspecified”; I61.3, “Intracerebral haemorrhage 
in brain stem”; I61.4, “Intracerebral haemorrhage in cerebellum”; I61.5, “Intracerebral 
haemorrhage, intraventricular”; I61.6, “Intracerebral haemorrhage, multiple localized”; I61.8, 
“Other intracerebral haemorrhage”; I61.9, “Intracerebral haemorrhage, unspecified”; I63.0, 
“Cerebral infarction due to thrombosis of precerebral arteries”; I63.1, “Cerebral infarction 
due to embolism of precerebral arteries”; I63.2, “Cerebral infarction due to unspecified 
occlusion or stenosis of precerebral arteries”; I63.3, “Cerebral infarction due to thrombosis of 
cerebral arteries”; I63.4, “Cerebral infarction due to embolism of cerebral arteries”; I63.5, 
“Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries”; I63.6, 
“Cerebral infarction due to cerebral venous thrombosis, nonpyogenic”; I63.8, “Other cerebral 
infarction”; I63.9, “Cerebral infarction, unspecified”; and I64.X, “Stroke, not specified as 
haemorrhage or infarction”. 
Respiratory infection: J12.X, “Viral pneumonia, not elsewhere classified: bronchopneumonia 
due to viruses other than influenza viruses”; J13, “Pneumonia due to Streptococcus 
pneumoniae”; J14, “Pneumonia due to Haemophilus influenzae”; J15.X, “Bacterial 
pneumonia, not elsewhere classified: bronchopneumonia due to bacteria other than S. 
pneumoniae and H. influenzae”; J18.0, “Bronchopneumonia, unspecified. Excluding 
bronchiolitis”; J18.1, “Lobar pneumonia, unspecified”; J18.2, “Hypostatic pneumonia, 
unspecified”; J18.8, “Other pneumonia, organism unspecified”; J18.9, “Pneumonia, 
unspecified”; J22, “Unspecified acute lower respiratory infection”; J44.0, “Chronic 
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obstructive pulmonary disease with acute lower respiratory infection. Excluding with 
influenza”; J44.1, “Chronic obstructive pulmonary disease with acute exacerbation, 
unspecified”; J69.0, “Pneumonitis due to food and vomit. Excluding Mendelson syndrome”; 
J69.1, “Pneumonitis due to oils and essences”; J69.8, “Pneumonitis due to other solids and 
liquids. Pneumonitis due to aspiration of blood”; and J85.1, “Abscess of lung with 
pneumonia. Excluding with pneumonia due to specified organism”. 
Acute myocardial infarction: I21.0, “Acute transmural myocardial infarction of anterior 
wall”; I21.1, “Acute transmural myocardial infarction of inferior wall”; I21.2, “Acute 
transmural myocardial infarction of other sites”; I21.3, “Acute transmural myocardial 
infarction of unspecified site”; I21.4, “Acute subendocardial myocardial infarction”; and 
I21.9, “Acute myocardial infarction, unspecified”. 
Pulmonary embolism/deep vein thrombosis: I80.1, “Phlebitis and thrombophlebitis of 
superficial vessels of lower extremities”; I80.1, “Phlebitis and thrombophlebitis of femoral 
vein”; I80.3, “Phlebitis and thrombophlebitis of other deep vessels of lower extremities”; 
I26.0, “Pulmonary embolism with mention of acute cor pulmonale”; and I26.9, “Pulmonary 
embolism without mention of acute cor pulmonale”. 
Urinary tract infection: N30.0, “Acute cystitis. Excluding irradiation cystitis and trigonitis”; 
and N39.0, “Urinary tract infection, site not specified”. 
Wound disruption: T81.3, “Disruption of operation wound, not elsewhere classified”. 
Surgical site infection: T81.4, “Infection following a procedure, not elsewhere classified”. 
Fracture after implant: M96.6, “Fracture of bone following insertion of orthopaedic implant, 
joint prosthesis, or bone plate. Excluding complication of internal orthopaedic devices, 
implants or grafts”. 
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Complication of prosthesis: T84.0, “Mechanical complication of internal joint prosthesis”. 
Neurovascular injury: T81.2, “Accidental puncture and laceration during a procedure, not 
elsewhere classified. Accidental perforation of: blood vessel, nerve or organ by: catheter, 
endoscope, instrument or probe during a procedure”. 
Acute renal failure: N17.0, “Acute renal failure with tubular necrosis”; N17.1, “Acute renal 
failure with acute cortical necrosis”; N17.2, “Acute renal failure with medullary necrosis”; 
N17.8, “Other acute renal failure”; and N17.9, “Acute renal failure, unspecified”. 
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Appendix 3. Operative procedure codes (OPCS 4.8) that we used to identify blood-
transfusion complication in the Hospital Episode Statistics (HES) registry. 
X33.2, “Intravenous blood transfusion of packed cells”; X33.3, “Intravenous blood 
transfusion of platelets”; X33.8, “Other specified other blood transfusion”; X33.9, 
“Unspecified other blood transfusion”; X33.1, “Intra-arterial blood transfusion”; X33.7, 
“Autologous transfusion of red blood cells”; X34.1, “Transfusion of coagulation factor”; 
X34.2, “Transfusion of plasma not elsewhere classified”; X34.3, “Transfusion of serum not 
elsewhere classified”; and X34.4, “Transfusion of blood expander”. 
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Appendix 4. Operative procedure codes (OPCS 4.8) that we used to identify knee revision in 
the Hospital Episode Statistics (HES) registry. 
Code Procedure 
Procedure type 1 
W40.0 Conversion from previous cemented total prosthetic replacement of knee joint 
W40.2  Conversion to total prosthetic replacement of knee joint using cement 
W40.3  Revision of total prosthetic replacement of knee joint using cement 
W40.4  Revision of one component of total prosthetic replacement of knee joint using 
cement 
W41.0  Conversion from previous uncemented total prosthetic replacement of knee joint 
W41.2 
 Conversion to total prosthetic replacement of knee joint not using cement 
W41.3 
 Revision of total prosthetic replacement of knee joint not using cement 
W41.4  Revision of one component of total prosthetic replacement of knee joint not using 
cement 
W42.0 
 Conversion from previous total prosthetic replacement of knee joint NEC 
W42.2 
 Conversion to total prosthetic replacement of knee joint NEC 
W42.3 
 Revision of total prosthetic replacement of knee joint NEC 
W42.4 
 Attention to total prosthetic replacement of knee joint NEC 
W42.5 
 Revision of one component of total prosthetic replacement of knee joint NEC 
W42.6 
 Arthrolysis of total prosthetic replacement of knee joint 
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W58.0 
 Conversion from previous resurfacing arthroplasty of joint 
O18.0  Conversion from previous hybrid prosthetic replacement of knee joint using 
cement 
O18.2 
 Conversion to hybrid prosthetic replacement of knee joint using cement 
O18.3 
 Revision of hybrid prosthetic replacement of knee joint using cement 
O18.4 
 Attention to hybrid prosthetic replacement of knee joint using cement 
Procedure type 2 
W52.0  Conversion from previous cemented prosthetic replacement of articulation of 
bone NEC 
W52.2 
 Conversion to prosthetic replacement of articulation of bone using cement NEC 
W52.3 
 Revision of prosthetic replacement of articulation of bone using cement NEC 
W53.0  Conversion from previous uncemented prosthetic replacement of articulation of 
bone NEC 
W53.2  Conversion to prosthetic replacement of articulation of bone not using cement 
NEC 
W53.3 
 Revision of prosthetic replacement of articulation of bone not using cement NEC 
W54.0 
 Conversion from previous prosthetic replacement of articulation of bone NEC 
W54.2 
 Conversion to prosthetic replacement of articulation of bone NEC 
W54.3 
 Revision of prosthetic replacement of articulation of bone NEC 
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W54.4 
 Attention to prosthetic replacement of articulation of bone NEC 
W55.3 
 Conversion to prosthetic interposition arthroplasty of joint 
W56.4 
 Conversion to interposition arthroplasty of joint NEC 
W57.4 
 Conversion to excision arthroplasty of joint 
W60.3 
 Conversion to arthrodesis and extra-articular bone graft NEC 
W61.3 
 Conversion to arthrodesis and articular bone graft NEC 
W64.1 
 Conversion to arthrodesis and internal fixation NEC 
W64.2 
 Conversion to arthrodesis and external fixation NEC 
Site for revision 
Z76.5  Lower end of femur NEC 
Z77.4  Upper end of tibia NEC 
Z78.7  Patella 
Z84.4  Patellofemoral joint 
Z84.5  Tibiofemoral joint 
Z84.6  Knee joint 
Procedure type 3 
W40.1  Primary total prosthetic replacement of knee joint using cement 
W40.8  Other specified total prosthetic replacement of knee joint using cement 
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W40.9  Unspecified total prosthetic replacement of knee joint using cement 
W41.1  Primary total prosthetic replacement of knee joint not using cement 
W41.8  Other specified total prosthetic replacement of knee joint not using cement 
W41.9  Unspecified total prosthetic replacement of knee joint not using cement 
W42.1  Primary total prosthetic replacement of knee joint NEC 
W42.8  Other specified other total prosthetic replacement of knee joint 
W42.9  Unspecified other total prosthetic replacement of knee joint 
O18.1  Primary hybrid prosthetic replacement of knee joint using cement 
O18.8  Other specified hybrid prosthetic replacement of knee joint using cement 
O18.9  Unspecified hybrid prosthetic replacement of knee joint using cement 
 
Algorithm: One code from procedure type 1 or a combination of one code from procedure 
type 2 and site for revision were used to identify knee revision. Combination of codes from 
procedures type 3 and type 1 or procedure type 3, type 2 and site of surgery identified knee 
revision after a primary knee unicompartmental replacement (UKR). 
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Appendix 5. Codes defined in the International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10) that we used to identify comorbidities in 
the Hospital Episode Statistics (HES) registry. 
Disease Codes 
Myocardial infarction I21, I22 
Congestive heart failure I50.0 
Peripheral vascular disease I70- I73 
Cerebrovascular disease I60-I67 
Dementia F00-F03 
Chronic obstructive pulmonary disease J41-J47 
Connective tissue disease M05, M06, M08, M15-M19, M35, M36 
Peptic ulcer disease K25-K28 
Mild liver disease K70.0, K76.0, K76.1 
Mild diabetes (without end organ damage - 
include ketoacidosis and coma) 
E10.X, E10.0, E10.1, E10.9, E11.X, E11.0, 
E11.1, E11.9, E12.X, E12.0, E12.1, E12.9, 
E13.X, E13.0, E13.1, E13.9, E14.X, E14.0, 
E14.1, and E14.9 
Hemiplegia G81 
Moderate/severe renal disease N17-N19 
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Severe diabetes (i.e. with organ damage) E10-E12, E13, or E14 complicated with .2-
.8, N083 
Tumour C00-C76, C80, C88, C90.0, C90.2, C96, 
C97, D00-D48 
Leukaemia C90.1, C91-C95 
Lymphoma C81- C85 
Moderate/severe liver disease K70-K76. Excluding codes for mild liver 
disease K70.0, K76.0 and K76.1 
AIDS B20-B23 
Metastatic solid tumour C77-C79 
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Table 1. Temporal trends in patients underwent planned primary TKR from April 2008 to 
December 2016. Full models with Newey-West standard errors. 
Parameter Coefficient Lower 
95% CI 
Upper 
95% CI 
P-value 
LOS 
    
   Intercept 5.871 5.852 5.890 <0.001 
   Monthly trend -0.032 -0.035 -0.028 <0.001 
   Level change ERAS0 0.158 0.106 0.210 <0.001 
   Trend change after ERAS0 0.002 -0.002 0.006 0.395 
   Level change ERASend -0.091 -0.171 -0.012 0.025 
   Trend change after 
ERASend 
0.016 0.013 0.018 <0.001 
OKS 6 months – OKS 
baseline   
 
 
   Intercept 14.020 13.376 14.664 <0.001 
   Monthly trend 0.052 -0.044 0.148 0.285 
   Level change ERAS0 0.261 -0.286 0.808 0.346 
   Trend change after ERAS0 -0.043 -0.146 0.059 0.404 
   Level change ERASend 0.325 0.003 0.647 0.048 
   Trend change after 
ERASend 
0.019 0.003 0.036 0.024 
Complication by 6 months      
   Intercept 4.049 3.936 4.162 <0.001 
   Monthly trend -0.058 -0.071 -0.045 <0.001 
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   Level change ERAS0 -0.807 -1.363 -0.250 0.005 
   Trend change after ERAS0 -0.003 -0.044 0.039 0.899 
   Level change ERASend 0.314 -0.074 0.702 0.112 
   Trend change after 
ERASend 
0.058 0.021 0.095 0.002 
Revision rates by 5 years     
   Intercept 4.833 4.597 5.068 <0.001 
   Monthly trend 0.014 -0.011 0.039 0.255 
   Level change ERAS0 -0.090 -0.313 0.133 0.418 
   Trend change after ERAS0 -0.031 -0.058 -0.003 0.031 
   Level change ERASend -0.095 -0.323 0.132 0.402 
   Trend change after 
ERASend 
0.040 0.021 0.060 <0.001 
Total knee replacement, TKR; confidence intervals, CI; length of stay at hospital, LOS; 
Oxford knee score, OKS; Enhanced Recovery Pathway, ERAS; start point of ERAS 
intervention in April 2009, ERAS0; end point of ERAS intervention in March 2011, ERASend. 
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DATA STATEMENT 
Access to data is available from the National Joint Registry for England and Wales, Northern 
Ireland and the Isle of Man, but restrictions apply to the availability of these data, which were 
used under license for the current study, and so are not publicly available. Data access 
applications can be made to the National Joint Registry Research Committee. Access to 
linked HES and PROMs data is available through data applications to NHS Digital. 
